课题基金 / 基金详情

The Discovery and Optimization of NUAK Inhibitors: A Novel Approach to Target Hippo Pathway Driven Cancers

The Discovery and Optimization of NUAK Inhibitors: A Novel Approach to Target Hippo Pathway Driven Cancers
NUAK 抑制剂的发现和优化：一种针对 Hippo 通路驱动的癌症的新方法
批准号：
434753
负责人：
Al-Awar Rima S
金额：
$37.9万
依托单位：
Ontario Institute for Cancer Research (Toronto, Ontario)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2020
资助国家：
加拿大
项目状态：
已结题
起止时间：
2020-10-01 至 2023-10-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=434753&lang=en
关键词：
Drug Discovery Hippo Pathway Kinase Inhibitors

项目摘要

项目成果

Al-Awar Rima S的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
A highly conserved group of proteins, referred to as the Hippo pathway, act to regulate cell and tissue growth. Virtually all solid tumors have disruptions in this critical signalling cascade and this drives processes that promote tumorigenesis. We recen
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Safety and efficacy of a possible epigenetic therapy for FSHD muscular dystrophy
海外基金